Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Endocrinology Laboratory, |
RCV001823858 | SCV002073529 | likely pathogenic | Bardet-Biedl syndrome 2 | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001885368 | SCV002138138 | pathogenic | Bardet-Biedl syndrome | 2023-12-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Val588Ilefs*9) in the BBS2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1339335). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV001823858 | SCV004214031 | likely pathogenic | Bardet-Biedl syndrome 2 | 2023-06-02 | criteria provided, single submitter | clinical testing |